Author Archives: Lu Rahman

#Covid-19 #Daiichi Sankyo #Drug discovery #Fujifilm Toyama Chemical #Japan #Takeda

Japanese drug development: Where is the innovation? 

Lu Rahman looks at how opportunities are growing in Japanese drug development and where innovation is coming from. Japan is a fascinating drug discovery and development market. A strong pharmaceutical sector (some reports place it second globally behind the US), an ageing population and a tranche of expertise, put the… Read More

#Editor's Choice #Exclusive Content #Market Reports

#Assay development optimisation & technology #BioDot #PCR

Considerations for scaling assays in life science

As the demand for assay data continues to grow and enabling technology allows us to generate huge datasets at impressive speeds, assay design is as critical as ever says Brian, Kirk, Vice President, Business Development, BioDot. While assay scaling has obvious benefits with respect to data analysis and providing answers… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Pistoia Alliance

 Building foundations for post-COVID-19 R&D

Dr. Steve Arlington and Dr. Nick Lynch, The Pistoia Alliance, provide insight into pre-competitive collaboration and data sharing as we thinks about R&D beyond the pandemic  At the Pistoia Alliance, our mission is to encourage collaboration across the life sciences ecosystem. We believe that scientific advances and breakthroughs cannot be… Read More

#Business & Investment

#BioAscent Discovery #Drug discovery

Opportunity knocks: why high quality leads matter

Does every cloud have a silver lining? Dr Phil Jones, Chief Scientific Officer, BioAscent Discovery outlines the opportunities for lead generation and the acquisition of compound screening libraries. The discovery of novel medicines is a complex but vital endeavour. The range of approaches being used to identify those new medicines… Read More

#Business & Investment

#Covid-19 #Data #Research & development

How to achieve data-driven R&D at speed

COVID-19 has shown the pace of innovation that is possible to develop vaccines and therapeutics. Matt Jones, Lead Data Scientist Strategist, Tessella explains how to set up R&D and data science teams to keep that going. The drive to develop new therapeutics and vaccines for COVID-19 saw researchers move at… Read More

#Business & Investment